Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,288)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00859001 | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy(FM+R-Z) | completed | Phase 2 | 55 | University of BolognaOTHER | 1 | Mar 12, 2009 | clinicaltrials |
| NCT00533728 | Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma | completed | Phase 1 | 12 | Biotec Pharmacon ASAINDUSTRY |
| 1 |
| Mar 4, 2009 |
| clinicaltrials |
| NCT00592579 | A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma | completed | Phase 2 | 60 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00850512 | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy(CHOP21+R-Z) | completed | Phase 2 | 55 | University of BolognaOTHER | 1 | Feb 25, 2009 | clinicaltrials |
| NCT00145613 | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | completed | Phase 2 | 25 | St. Jude Children's Research HospitalOTHER | 1 | Feb 13, 2009 | clinicaltrials |
| NCT00285389 | Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years | completed | Phase 2 | 39 | French Innovative Leukemia OrganisationOTHER | 1 | Feb 12, 2009 | clinicaltrials |
| NCT00200681 | IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma | completed | Phase 3 | 493 | Nantes University HospitalOTHER | 1 | Feb 5, 2009 | clinicaltrials |
| NCT00291538 | Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma | completed | Phase 1 | 20 | Nantes University HospitalOTHER | 1 | Feb 4, 2009 | clinicaltrials |
| NCT00834951 | Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 40 | University of AarhusOTHER | 0 | Feb 3, 2009 | clinicaltrials |
| NCT00143559 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | completed | Phase 2 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00152139 | Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 3 | 33 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00207805 | The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma | completed | Phase 3 | 202 | Centre National de Greffe de Moelle OsseuseOTHER_GOV | 1 | Jan 27, 2009 | clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00193544 | Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Jan 23, 2009 | clinicaltrials |
| NCT00579917 | Behavioral Intervention For BMT/SCT Survivors(BMT/SCT) | completed | — | 133 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2009 | clinicaltrials |
| NCT00560053 | Pethema Multiple Myeloma 2000 | completed | Phase 3 | 500 | PETHEMA FoundationOTHER | 0 | Nov 27, 2008 | clinicaltrials |
| NCT00696735 | High-Dose Therapy Treatment in Patients With Follicular Lymphoma | completed | Phase 3 | 172 | French Innovative Leukemia OrganisationOTHER | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00161590 | Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma | completed | Phase 1 | — | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 22, 2008 | clinicaltrials |
| NCT00204659 | Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | Oct 20, 2008 | clinicaltrials |
| NCT00001120 | A Study of Patients With AIDS Syndrome | completed | — | 5,000 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Sep 12, 2008 | clinicaltrials |
| NCT00290004 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 35 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 11, 2008 | clinicaltrials |
| NCT00347971 | Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma | completed | Phase 1 | 23 | ZymoGeneticsINDUSTRY | 1 | Sep 5, 2008 | clinicaltrials |
| NCT00196885 | Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training | completed | Phase 2 | 60 | German Cancer Research CenterOTHER | 1 | Jun 20, 2008 | clinicaltrials |
| NCT00017680 | Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis | completed | Phase 2 | 25 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2008 | clinicaltrials |
| NCT00187161 | Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL | completed | Phase 2 | 68 | St. Jude Children's Research HospitalOTHER | 1 | Jun 4, 2008 | clinicaltrials |
| NCT00177554 | Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma | completed | Phase 2 | 60 | University of PittsburghOTHER | 1 | May 29, 2008 | clinicaltrials |
| NCT00113204 | Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma(IPi-504-01) | completed | Phase 1 | 18 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2008 | clinicaltrials |
| NCT00187070 | Large Cell Lymphoma Pilot Study III | completed | N/A | 8 | St. Jude Children's Research HospitalOTHER | 1 | May 7, 2008 | clinicaltrials |
| NCT00320476 | VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates | completed | Phase 2 | 35 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00187122 | Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma | completed | N/A | 42 | St. Jude Children's Research HospitalOTHER | 1 | Apr 23, 2008 | clinicaltrials |
| NCT00633542 | Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) | completed | Phase 3 | 103 | Università Politecnica delle MarcheOTHER | 1 | Mar 12, 2008 | clinicaltrials |
| NCT00050999 | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients | completed | Phase 4 | 195 | Eisai Inc.INDUSTRY | 10 | Mar 5, 2008 | clinicaltrials |
| NCT00051012 | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients | completed | Phase 4 | 86 | Eisai Inc.INDUSTRY | 9 | Mar 5, 2008 | clinicaltrials |
| NCT00001237 | Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001301 | Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors | completed | — | 107 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001430 | A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001567 | A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001571 | A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines | completed | — | 20 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001750 | Comparing Treatments for Multiple Myeloma | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00026910 | Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma | completed | — | 200 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00066092 | Pegfilgrastim PBPC Mobilization Study | completed | Phase 2 | 41 | AmgenINDUSTRY | 0 | Feb 28, 2008 | clinicaltrials |
| NCT00063713 | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 152 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00085696 | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma | completed | Phase 2 | 66 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00257114 | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability | completed | Phase 4 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00090090 | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 114 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jan 15, 2008 | clinicaltrials |
| NCT00044902 | Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade) | completed | Phase 2 | — | AmgenINDUSTRY | 0 | Dec 28, 2007 | clinicaltrials |
| NCT00116441 | Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00086216 | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 30 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Mar 12, 2009source: clinicaltrials